Positive DARRT-1 Data in Late-Stage Prostate Cancer
December 02, 2019 09:00 ET | Noxopharm
Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger planning for proposed pivotal...
Noxopharm Announces Appointment of Chief Commercial Officer
November 06, 2019 09:26 ET | Noxopharm
Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth listed company operations...
Potential for Fundamental Change in the Treatment of Brain Cancer
October 18, 2019 09:13 ET | Noxopharm
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international...
Further Data Review Shows Major Clinical Benefits From Veyonda®
September 30, 2019 08:00 ET | Noxopharm
Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer177LuPSMA therapy is the subject of a recent...
Veyonda® and Radiotherapy Profiled at Key Oncology Meeting
September 17, 2019 11:01 ET | Noxopharm
Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meetingBoth Noxopharm and independent investigators have abstracts...
Media Statement Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment Further Promising Results
August 28, 2019 07:57 ET | Noxopharm
SYDNEY, Australia, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on...
Pre-Clinical Evidence Confirms Veyonda® Abscopal Effect
August 21, 2019 08:12 ET | Noxopharm
Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effectPre-clinical studies now...
Appendix 4C– June 2019 Quarter
July 29, 2019 08:00 ET | Noxopharm
Positive results from two prostate cancer trialsPhase 2 trial design gaining momentumInvestigational New Drug Application to be submitted to FDA in Q3 2019Pipeline developing based on drug discovery...